Strong evidence · Grade A
Thymosin Alpha-1
Thymosin Alpha-1 (Zadaxin)
Score
80 / 100
Class
Immune-modulating peptide
Brand
Zadaxin
Status
Approved ~30 countries (not FDA)
TL;DR
01
A 28-amino-acid immune-modulating peptide (Zadaxin/thymalfasin), the genuinely drug-grade member of this group — approved in ~30 countries (though not by the US FDA).
02
Its strongest evidence is in chronic hepatitis B: meta-analyses show that adding it to antiviral therapy improves seroconversion and virologic response.
03
It restores and rebalances T cells, which is why it's used as an immune-support adjunct in infections, sepsis, and as a cancer-treatment add-on.
04
During COVID-19 it was associated with lower mortality in severe cases — but that key study was retrospective, a weaker design than a randomized trial.
05
It is very well tolerated, but it is not FDA-approved, and much of its evidence is adjunctive rather than standalone.
Hepatitis B (meta-analysis)
Improves seroconversion
45% vs 15% adjunct to lamivudine
Mechanism
T-cell restoration
reverses exhaustion/lymphopenia
COVID severe
Lower mortality
11% vs 30% (retrospective)
US approval
Not FDA-approved
approved in ~30 countries
Tolerability
Very good
decades of use
Part 01 · How it works
Mechanism.
Thymosin alpha-1 is a peptide the thymus naturally makes to educate and balance the immune system. As a drug (Zadaxin), it boosts and rebalances T cells — helping an exhausted or depleted immune response recover. That's why its best evidence is in chronic hepatitis B, where adding it to antivirals improves the odds of clearing the infection, and why it's used as an immune adjunct in sepsis, other infections, and alongside cancer therapy. It's a real, approved medicine in much of the world — just not in the US, and much of its value is as an add-on rather than a cure on its own.
An immune-system coach that gets tired or depleted T cells back in the game. It rarely wins the match alone, but as an add-on it measurably improves the team.
T-cell modulation
Promotes T-cell maturation and function, restores CD4/CD8 counts, and reverses T-cell exhaustion (lower PD-1/Tim-3).
Thymic output
Increases thymic output (measured by TRECs) during immune suppression.
Antiviral adjunct
Improves biochemical/virologic response and HBeAg seroconversion when added to hepatitis B antivirals.
Evidence stage
Multiple trials and meta-analyses; approved in ~30 countries; not FDA-approved.
Part 02 · Dosing & administration
How it's taken.
Clinical · trial-validatedValues below describe how Thymosin Alpha-1 has been administered in human clinical trials and/or approved labeling. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.
Clinical
1.6 mg twice weekly
Typical Zadaxin regimen (varies by indication); prescribed where approved.
·
Doses below are from labeling where approved, not instructions.
·
Given by subcutaneous injection; regimen varies by indication.
·
Not FDA-approved in the US; availability depends on jurisdiction.
Need help with reconstitution?
Use the free peptide calculator for dilution, unit conversion, and injection volume.
Part 03 · Safety
Side effects, rare serious events, who shouldn't.
Common
Injection-site reactions
Generally mild.
Common
Transient fatigue
Mild, transient.
Occasional
Serious · rare
Immune modulation
As an immune stimulant, theoretical caution in autoimmune disease.
Consideration
Hypersensitivity
Discontinue for serious allergic reaction.
Rare
Absolute · do not use
×
Pregnancy or breastfeeding
×
Children under 18 (unless under specialist care)
×
Known hypersensitivity to thymosin alpha-1 or any component
×
Organ transplant recipients on immunosuppression (risk of graft rejection)
×
Active autoimmune disease in flare (may exacerbate autoimmunity)
Relative · discuss first
!
Autoimmune disease — immune-stimulating mechanism, use with caution
!
Organ transplant / immunosuppression — could counteract intended suppression
!
Pregnancy or breastfeeding — limited data
!
Expecting a standalone cure — benefit is largely adjunctive
Interactions
Immunosuppressants (tacrolimus, cyclosporine)
Thymosin alpha-1 stimulates T-cell and dendritic cell function; directly opposes immunosuppressive therapy
Major
Immune checkpoint inhibitors
Additive immune activation; increased risk of immune-related adverse events
Moderate
Interferon-alpha
Often used in combination for hepatitis B/C; additive immune activation with potential for enhanced efficacy but also increased side effects
Moderate
Corticosteroids
High-dose corticosteroids may reduce thymosin alpha-1 efficacy by suppressing immune function
Moderate
Labs to monitor
CBC with Differential
Baseline and monthly
Monitor immune cell counts and T-cell response
T-Cell Subsets (CD4, CD8)
Baseline and at end of treatment
Primary mechanism is T-cell activation
CMP (Comprehensive Metabolic Panel)
Baseline and every 3 months
Liver function (used in hepatitis B treatment)
Hepatitis B Viral Load
Per hepatology protocol
If used for HBV (approved indication in some countries)
CRP / ESR
Baseline and monthly
Track inflammatory/immune markers
Part 04 · Evidence
How strong is the evidence?
80
Grade A
Grade A. Thymosin alpha-1 is a genuinely evidenced, internationally approved immune-modulating drug with meta-analytic support in hepatitis B and a strong safety record. The caveats: no US FDA approval, some evidence (e.g., COVID) is retrospective, and much of its value is adjunctive.
Mechanistic plausibility
Well-characterized T-cell/immune-restoration mechanism.
84
Human evidence
Multiple trials and meta-analyses (hepatitis B); broad international use.
82
Safety & tolerability
Very well tolerated across decades of clinical use.
85
Durability
Effect tied to treatment course; mostly adjunctive benefit.
72
Independence
Independent meta-analyses exist, but some supporting studies (e.g., COVID) are retrospective/lower quality.
70
Part 05 · Research log
Every study we cite.
We list each study with its methodology, funding source, and our quality grade. Flagged studies aren't dismissed — they're tagged so you can weigh them.
01
2009
Virology Journal Flagged
Lamivudine vs lamivudine + thymosin alpha-1 in HBeAg-positive chronic hepatitis B — meta-analysis
Adding thymosin alpha-1 improved ALT normalization (80% vs 69%), virologic response (85% vs 75%), and HBeAg seroconversion (45% vs 15%) versus lamivudine alone.
Meta-analysis of 8 trials · n = 583 · Pooled trials of varying quality; consistent adjunctive benefit.
PMID 19467157 ↗
Moderate-High
02
2020
Clinical Infectious Diseases Flagged
Thymosin alpha-1 reduces mortality of severe COVID-19
Associated with lower mortality (11.1% vs 30.0%) and restored T-cell counts / reversed exhaustion in severe COVID-19 — but retrospective, not randomized.
Retrospective cohort (2 Wuhan hospitals) · n = 76 · Retrospective design cannot establish causation; encouraging but not definitive.
PMID 32442287 ↗
Low-Moderate
Evidence against
What didn't work, and where the evidence is thin.
Every publication is incentivized to tell you a peptide works. We catalogue the null results, failed trials, and mechanism limits we found in the same literature — so you can weigh them against the upside, with your provider.
01
Not FDA-approved, and key non-hepatitis evidence is retrospective
Mechanism limit Clinical Infectious Diseases · 2020
Despite decades of use and orphan/fast-track history, thymosin alpha-1 is not FDA-approved. Some high-profile evidence (e.g., the COVID-19 mortality benefit) comes from retrospective studies, which are prone to confounding.
What this means: Strong for hepatitis B by meta-analysis, but weaker and less controlled elsewhere. The US regulatory absence and reliance on retrospective data temper the broader claims.
PMID 32442287 ↗
02
Benefit is largely adjunctive
Mechanism limit Virology Journal · 2009
Its clearest wins are as an add-on to other therapy (e.g., improving antiviral response in hepatitis B), not as a standalone treatment.
What this means: It's an immune-support adjunct, not a primary cure. Expectations should match that role.
PMID 19467157 ↗
Part 06 · Cost & access
Where it's available, at what price.
United States
Not FDA-approved
Not approved; sometimes accessed via compounding. Not a standard US therapy.
Varies / grey-market
China / Asia
Approved
Widely used (Zadaxin) for hepatitis B/C, immune support, and as a cancer adjunct.
Regional markets
European Union
Approved (varies)
Approved/used in several countries (e.g., Italy).
Varies
United Kingdom
Not routine
Not a routine NHS product.
N/A
The Peptide Column takes no affiliate commission from any source. Thymosin alpha-1 (Zadaxin) is an approved immune-modulating medicine in many countries but not in the US; where used, it is prescription-only. We link only to clinician-directed care, never to sellers.
Part 07 · Your appointment
Questions to bring.
01
Is Thymosin Alpha-1 available through legitimate pharmaceutical channels (Zadaxin) versus research peptide suppliers?
02
Given my specific condition, does the evidence support Thymosin Alpha-1 use and what dosing protocol is appropriate?
03
Are there any interactions with immunosuppressive medications I may be taking?
04
What monitoring is recommended to assess immune response during treatment?
References
Every citation, numbered.
Citation list. For our editorial read of each study — including bias flags and quality grades — see the Research log above.
- 01. Lamivudine vs lamivudine + thymosin alpha-1 in HBeAg-positive chronic hepatitis B — meta-analysis · Virology Journal, 2009 · PMID 19467157 ↗
- 02. Thymosin alpha-1 reduces mortality of severe COVID-19 · Clinical Infectious Diseases, 2020 · PMID 32442287 ↗
- 03. Prescribing information (int'l). Zadaxin (thymalfasin) labeling where approved